Evoke Pharma Inc

of this Current Report on Form 8-K is incorporated by reference into this Item 5.02. In connection with the consummation of the Merger, each of Cam L. Garner, M

. In connection with the consummation of the Offer and the Merger, the Company notified The Nasdaq Capital Market (“Nasdaq”) of the consummation of the Merger a

. Item 5.01 Changes in Control of Registrant. The information set forth under Items 2.01, 5.02, and 5.03 of this Current Report on Form 8-K is incorporated by r

. As a result of the completion of the Offer and the subsequent completion of the Merger, a change of control of the Company occurred and the Company became a w

Departure of Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. The information set forth

Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year. Pursuant to the terms of the Merger Agreement, on December 17, 2025, the Company’s cer

Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description of Exhibit 2.1 Agreement and Plan of Merger, dated November 3, 2025, by and among QOL M